The last decade has witnessed the emergence of international ethics guidelines discussing the importance of disclosing global and also, in certain circumstances, individual genetic research results to participants. This discussion is all the more important considering the advent of pharmacogenomics and the increasing incidence of 'translational' genetic research in the post-genomic era. We surveyed both the literature and the ethical guidelines using selective keywords. We then analyzed our data using a qualitative method approach and singled out countries or policies that were representative of certain positions. From our findings, we conclude that at the international level, there now exists an ethical duty to return individual genetic research results subject to the existence of proof of validity, significance and benefit. Even where these criteria are met, the right of the research participant not to know also has to be taken into consideration. The existence of an ethical duty to return individual genetic research results begs several other questions: Who should have the responsibility of disclosing such results and when? To whom should the results be disclosed? How? Finally, will this ethical 'imperative' become a legally recognized duty as well?
Introduction
The last decade has witnessed the emergence of international ethics guidelines individual to genetic research involving humans (Table 1) . Focusing mainly on these international texts, is there an ethical obligation on researchers to disclose genetic research results to participants or even to provide access to them? Authors of a recent article on the return of research results contend that: 'There are no conditions under which an offer of disclosure of research results should not be made. ' 1 This approach is problematic in that whereas on the one hand, the return of clinical trial results (Table 2) relevant to health has long been the norm, 2,3 on the other hand, fundamental research (Table 2 ) results are by their very nature not individually identifiable, understandable or significant. Early genetic association studies imperfectly predict the development and severity of a condition. Associations with disease are often not validated in more extensive studies and could mislead participants to overestimate the significance of the results. 4, 5 Indeed, 'the difficulty in deciding whether to return research results lies in the fact that exploratory genetic factors have not yet reached the point of general clinical acceptance.' 6 Yet, it is self-evident that ongoing communication with participants is important in order to respect their voluntary decision to continue or to withdraw once they have agreed to participate in research as well as to recognize the importance of their altruistic contribution to the progress of research in the field of genetics. Table 2 ) research is increasingly surfacing in the field of genetics. Seemingly, returning individual fundamental research results is impossible and nonsensical as the very purpose of this type of research is not the production of individual but generalizable knowledge. Thus, in this context, the concept of individual research results is a scientific misnomer. To avoid confusion, both translational research and the clinical trial context where the individual receives a drug or undergoes some intervention (or even a placebo) need to be distinguished from fundamental research.
Beginning then with a brief contextual snapshot of the international guidelines demonstrating the emergence of an ethical duty to share genetic research results (along with Table 2 The research continuum Clinical trials Any investigation in human research participants intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy (see International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Guidance for Industry E6 Good Clinical Practice Consolidated Guideline, Geneva, 1996) the existence of the right not to know) (A), the issues of which genetic results and when? (B), by whom? (C) and, to whom? (D), need to be addressed before concluding (E). Guidelines are neither standards nor laws. But, if over time they become professional norms, they may become the legal standard of care for both clinical practice and for research.
Materials and methods
In order to identify and assess international perspectives on the return of research results, we undertook an empirical analysis of both the literature and the ethical guidelines found on major electronic databases using selective keywords. However, publishing clinical research results in a scientific journal or in a regulatory database is no longer ethically sufficient. The ethical principles of respect for the person, beneficence and justice obligate the researcher to offer results in a manner that is clear and understandable to the research participants. 1, 17 The recent draft guidelines of the European Federation of the IEA) state that, Research results should be published without undue delay, and disseminated critically and in good faith, supported by proper documentation. Findings that contradict the main results should always be presented in the text. It is advisable to publish the main results in a form that reaches the participants of the study and other interested members of the community where the study took place (eg a newsletter, local newspapers etc.) (emphasis added). 8 Communication can take the form of a personal letter, a news bulletin, a newspaper article, website or a similar forum. In the actual context, the chosen media should be specified at the beginning of the consent process. Such transparency in the communication of global results (often the only benefit from research) is not the same, however, as giving back individual results.
Individual research results
To illustrate the evolution of the concept of returning individual research results, the 1991 Council for International Organizations of Medical Sciences (CIOMS) International Guidelines for Ethical Review of Epidemiological Studies maintained that being informed of findings 'that pertain to their health' is one of the 'reasonable' benefits of participation for 'communities, groups and individuals' in research. 18 A decade later, this position was underscored by CIOMS by not only suggesting informing participants of the findings of the research in general but also by clarifying that 'individual subjects will be informed of any finding that relates to their particular health status' (emphasis added). 10 A similar position was also expressed by the Council of Europe 19 and, in the specific context of genetic research, by UNESCO 20 and the WHO (World Health Organization). 21 All these international guidelines also recognize the logical a contrario position, that of the 'right not to know'. The emergence of this nebulous 'right not to know' further confounds the determination of whether an ethical duty to return genetic research results exists. Indeed, this right depends on the informed consent process and therefore needs to be discussed before the research even begins. At that time, the participant can exercise a choice concerning possible future communication of research results.
The right not to know was legally consecrated in the 1997 Council of Europe's Convention on Human Rights and Biomedicine. 22 The Convention is a legally binding instru- 
(B) Which genetic research results and when?
International guidelines generally address neither the specific issue of which results nor the timing of their communication, except the obvious obligation to 'inform a subject when medical care is needed'(4.3.2). 3 We have already noted the position of CIOMS on the return of any finding that relates to particular health status. 8 Thus, can we presume a duty to return global results to all participants as well as the need to return individual results if reliable and clinically significant? Nowhere is this more problematic than in the specific context of genetic research. This is because, 'human genetic research is not conducted with the aim of providing research participants with specific information about their genetic status or health. Generally, genetic information derived from research is of unknown or uncertain predictive value. Therefore, special care must be taken to prevent inadvertent release of immature data' (emphasis added). 26 The 2002 Consortium on Pharmacogenetics maintains that 'researchers are obligated to offer the research participant the option of disclosure of research information when its reliability has been established and when the disclosure is of potential benefit to the subject' (emphasis added). 27 The Consortium, however, did not attempt to define what would constitute 'potentially beneficial' or 'reliable' results, presumably preferring to leave a margin of professional interpretation to the research team. According to the Pharmacogenetics Working Group, the issue of whether to disclose also depends on other criteria such as the standard operating procedure of the research sponsor, the scientific validity, the clinical relevance, quality assurance, the measures to maintain confidentiality, the ability of researchers or sponsors to provide the appropriate counselling, the legal and ethical framework, etc. 6, 28 A distinction must be made between pharmacogenetic drug trials where it could be considered a requirement to disclose individual results of direct interest and benefit to the participant and hypothesis testing studies of no direct medical relevance which would not need to be shared with the participant. 27 (a) 'the data have been instrumental in identifying a clear clinical benefit to identifiable individuals; (b) the disclosure of the data to the relevant individuals will avert or minimize significant harm to those individuals; (c) there is no indication that the individuals in question would prefer not to know.' 21 In short, if individual genetic research results are to be returned at all, at a minimum, they should meet the requirements of scientific validity, clinical significance, benefit (ie existence of prevention or treatment) and the absence of an explicit refusal to know. However, it could well be that a result that has no clear clinical benefit at the time of the research will turn out to be very important to the participant at a later time. This raises the question of how long can the ethical duty to return results last? Members from the Pharmacogenetics Working Group have recently suggested that 'some pragmatic limitations on the research endeavor should be put in place so that responsibilities of investigators, sponsors, participants, and ethics committees are not left open ended.' 6 More specifically, the American National, Heart, Lung, and Blood Institute (NHLBI) Working Group on Reporting Genetic Results in Research Studies stipulates that 'responsibilities of the investigators cannot extend beyond the period of funding.' 4 The requirements of validity, significance, and benefit could be assessed by answering the following questions:
(1) 'Does the genetic test that generated the results accurately identify the genetic variant of interest?
(2) Does the identification of the variant permit an accurate prediction of the presence (or risk) of a clinical condition? (3) Can the identification of the clinical condition (either disease or risk for developing a disease) improve the patient's health outcome?' 30 To be truly effective, evaluation methods to assess the clinical significance of genetic tests will need to be as complete and unbiased as possible. 30 In the past, when the above three criteria were met, the researcher retained discretion over the decision to communicate research results or not. Recent international norms now suggest an ethical obligation to disclose all research results meeting these criteria. This is illustrated by the 2004 Additional Protocol to the Convention on Human Rights and Biomedicine Concerning Biomedical Research recently issued by the Council of Europe; 'If research gives rise to information of relevance to the current or future health or quality of life of research participants, this information must be offered to them' (emphasis added). 19 But how can one determine what is relevant for each research participant? For example, an argument could be made that an information about a genetic predisposition can be relevant to the participant even though it is unlikely to affect immediate health outcomes (eg lifestyle). One solution, advanced by the Pharmacogenetics Working Party, would be to subject research findings to both peer review and ethics review before disclosure. 31 The NHLBI Working Group on Reporting
Genetic Results in Research Studies also maintains that decisions regarding reporting of research results should only be made with IRB approval. 4 It remains to be seen what will be the effect of this extensive duty on genetic research results. An important precaution that genetic researchers would be wise to take is to validate their research results via a licensed or accredited clinical laboratory. This is in fact a legal obligation in the United States. 32, 33 However, this solution might be difficult to implement in some countries as the qualities, accessibility and availability of tests vary greatly and validating research results in a clinical laboratory is not always economically feasible for researchers.
(C) By whom? While this obligation to disclose both individual and global genetic results is developing, few guidelines at the international level specify with whom this duty lies. Generally, no person is named specifically to carry out this task. The Pharmacogenetics Working Group also makes a specific suggestion: according to them, 'the subject's physician may be in the best position thoughtfully to communicate these results as part of follow-up healthcare contacts'. 28 Neither UNESCO nor WHO address this topic in their recent norms governing genetic data. 20, 21 At the national level, several groups have come up with suggestions. According to the Consortium on Pharmacogenetics, the consent form should state who will make the determination of reliability and who will have the responsibility of informing the participants. 27 Canada's three granting councils, in their Policy Statement, seem to recommend that the genetic researcher be the one to report results back to the individuals: 'The genetic researcher shall seek free and informed consent from the individual and report results to that individual if the individual so desires.' 9 However, even they recognize that 'considerations should be given to combining clinical expertise with that of the research geneticist.' 9 Thus, it could be posited that the participant's treating physician or at the very least a clinician involved with the research team would be an appropriate person to report the research results rather than the researcher. However, this implies that from that point on, the research findings will be entered in the medical record of the research participants. They then will be afforded the same level of confidentiality protection as any other kind of medical information.
Another important person to involve in the process is the genetic counselor. In recent applications, concerning research projects on predictive testing, pre-and post-test genetic counseling is seen as integral to the research. Both researchers and the institutional review board now have to ensure the availability of such counseling when appropriate, 9 Disclosure in these circumstances is permissible even in the face of objection from the person who originally contributed data to the database. The onus is on those who would seek to disclose to justify this action. Ethical approval for such disclosures should be sought. 21 Acknowledging that 'an individual's privacy interest in his genetic information might not be absolute' yet fully realizing the complexity of the issues involved, the Pharmacogenetics Working Group recommended that any decision regarding familial disclosure be made on a case-by-case basis. 6 
Conclusion
Resolution of the question of whether there is a duty to return global or individual genetic research results depends on the type of study, the clinical significance and reliability of the information, and whether the study involves patients, genetically 'at-risk' families for a tested predisposition or healthy volunteers. Further confounding the emerging duty to return genetic research results is the situation in which the researcher is also a clinician and the participant is also a patient.
However handled, the issue of notifying (or not) participants of results should be disclosed and agreed to in advance (ie on the consent form). As stated by the European Commission in 2004: lie on the consent form Public trust in research surrounding genetic testing is largely dependent on how the use of samples and data in and from biobanks is undertaken and communicated. This applies in particular to [t]he communication of study results and, where appropriate, of individual test results. 17 Finally, although at the international level there may be an emerging ethical 'imperative' to return results in genetic research, this begs the further question of whether this duty should be legally recognized. It is hoped that fear of potential legal liability will not give rise to protectionist approaches mandating such a duty under law. Like research 'results', an ethical 'imperative' is also a misnomer, for the ethics of decision-making in the research context depends on dialogue and agreement between participants and researchers.
